RenataDHA:RENATA 85 Days Payable is 20.72 as of Mar. 2026, which is 87% above its 10-year median of 11.06. GuruFocus rates DHA:RENATA with a GF Score™ of 85/100 and a GF Value™ of BDT810.62 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, Renata ranks worse than 96.1% on this metric.
Renata's average Accounts Payable for the
three
months ended in Mar. 2026 was BDT1,420 Mil. Renata's Cost of Goods Sold for the
three
months ended in Mar. 2026 was BDT6,254 Mil.
Hence, Renata's Days Payable for the
three
months ended in Mar. 2026 was 20.72.
The historical rank and industry rank for Renata's Days Payable or its related term are showing as below:
DHA:RENATA'
s Days Payable Range Over the Past 10 Years
Min: 8.46 Med: 11.06 Max: 18.69
Current: 18.69
During the past 13 years, Renata's highest Days Payable was 18.69. The lowest was 8.46. And the median was 11.06.
DHA:RENATA's Days Payable is ranked worse than 96.1% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs DHA:RENATA: 18.69
Renata's Days Payable
increased
from Mar. 2025 (18.50) to Mar. 2026 (20.72).
It may suggest that Renatadelayed paying its suppliers.
Renata Days Payable Related Terms
Renata Days Payable Historical Data
* Premium members only.
The historical data trend for Renata's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:RENATA vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Renata's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renata Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Renata's Days Payable distribution charts can be found below:
* The bar in red indicates where Renata's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Renata's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renata (DHA:RENATA) has a Days Payable of 20.72 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Renata and its competitors. This is 87% above median its historical median of 11.06. Over the past decade, Renata's Days Payable has ranged from 8.46 to 18.69. According to the industry distribution chart, Renata ranks #886 out of 922 companies in the Drug Manufacturers industry, placing it in the top 96.1%.
Is Renata's Days Payable too high?
Renata's current Days Payable of 20.72 is 87% above median its 10-year median of 11.06. Over the past 10 years, this metric has ranged from a low of 8.46 to a high of 18.69. The Drug Manufacturers industry median Days Payable is 90.61. Renata's value of 20.72 is 77.1% below this industry median. Based on the distribution chart, Renata ranks #886 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Renata has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Renata's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Renata ranks #886 out of 922 companies for Days Payable. This places Renata in the lower half of its industry. The industry median Days Payable is 90.61. Renata's value of 20.72 is 77.1% below this benchmark. Historically, Renata's own Days Payable has ranged from 8.46 to 18.69 over the past decade. While the company's 10-year median is 11.06 vs. the industry median of 90.61, Renata has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renata's current Days Payable of 20.72 is 77.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Renata and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renata's current Days Payable is 20.72, which is 87% above median its own 10-year median of 11.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renata stock overvalued right now?
Based on GuruFocus' analysis, Renata (DHA:RENATA) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT810.62, compared to a current price of BDT456.40 — trading 43.7% below its estimated fair value. The current Days Payable is 20.72, which is 87% above median its 10-year median of 11.06 and 77.1% below the Drug Manufacturers industry median of 90.61. Renata's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Renata (DHA:RENATA), the current Days Payable is 20.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renata (DHA:RENATA) Overvalued in 2026?
Based on GuruFocus' analysis, Renata stock appears to be undervalued.
The current stock price of BDT456.40 is trading 43.7% below its estimated GF Value™ of BDT810.62.
GuruFocus considers Renata to be Significantly Undervalued.
Key valuation signals for DHA:RENATA:
Days Payable: 20.72 (87% above median its 10-year median of 11.06)
GF Value™: BDT810.62 vs. price of BDT456.40 (43.7% below fair value)
Industry Position: 77.1% below the Drug Manufacturers median (#886 of 922)
No single metric tells the full story. See the DHA:RENATA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
85GF Score
Get the complete analysis for DHA:RENATA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:RENATA has been successfully added to your 
